Chelsie Derman

Patients with hereditary angioedema report greater rates of autoimmune diseases, allergies, and asthma than the general population, highlighting key comorbidities.

A study highlights how food allergies impact adults' mental health and social lives, revealing anxiety, isolation, and the need for better support systems.

Lugar spoke with HCPLive about when to refer patients with suspected ISM to an allergist, highlighting allergic manifestations, diagnostic clues, and misconceptions.

HCPLive spoke with Lugar on indolent systemic mastocytosis’ allergic manifestations and diagnostic markers.

The phase 3 REALISE study found EPIT with VP250 had a strong safety profile, with severe adverse events dropping from 9.7% in year 1 to 0.3% in year 3.

New ACP migraine guidelines recommend adding a triptan to NSAIDs or acetaminophen for better relief. Combination therapy offers greater pain relief and fewer rescues.

A study found ceftriaxone was the most common drug to lead to anaphylaxis in children.

A new study highlights key risk factors of cold-induced anaphylaxis, including genetic markers and elevated IgE, expanding on findings from the COLD-CE study.

A narrative review reports the connection between allergies and sleep and available treatment options for both conditions.

Among 162 patients in the study, 99% reported satisfaction of sublingual immunotherapy with real grocery store food.

A cross-sectional cohort study identified several factors linked to eyewash use among individuals with allergic rhinitis.

With a new FDA goal date in June, ketamine is one step closer to receiving approval for anesthesia, sedation, pain, mental health, and neurological indications.

This month in review covers key psychiatry updates, including the latest FDA decisions, antidepressant use in pregnancy, and the latest episode of Medical Ethics Unpacked.

At AAAAI, Golden discussed when to test for insect sting allergies, the role of venom immunotherapy, and the potential impact of epinephrine nasal spray.

This February 2025 month in review covers key updates in allergy, including advancements in immunotherapy and new insights on food allergy desensitization.

At AAAAI 2025, David Golden, MD, discussed when to test for insect sting allergies, the role of mast cell disorders, and updated guidelines for all ages.

HCPLive spoke with Golden at AAAAI on the pitfalls of diagnosing all patients with insect stings for insect sting allergies.

HCPLive spoke with Lam at AAAAI about how allergists should establish endoscopic sinus surgery expectations with patients regarding risks and benefits ahead of the operation.

A phase 2 trial found that 100% of children on peanut oral immunotherapy tolerated 9043 mg of peanuts, vs 10% in the avoidant group.

Phase 2 data from AAAAI 2025 shows peanut oral immunotherapy boosts desensitization in children with high-threshold peanut allergy, enabling safe meal-size peanut consumption.

Although omalizumab demonstrated superiority over oral immunotherapy, the treatments had comparable effectiveness when excluding dropouts from the analysis, Wood said at AAAAI.

A Johns Hopkins study presented at AAAAI 2025 found omalizumab was more effective than oral immunotherapy for food allergies, with fewer dropouts due to adverse events.

Climate change is increasing pollen and tick-related allergies, said Scott Commins, MD, PhD, at AAAAI 2025.

A study found that oral physiological changes from allergen exposure in Oral Allergy Syndrome do not alter Anaphylm’s pharmacokinetic or pharmacodynamic profiles.

At AAAAI 2025, HCPLive spoke with Mahdavinia about how climate change impacts allergies.

HCPLive spoke with Cohen about how patients with a peanut allergy responded to oral immunotherapy with autoclaved peanuts.

HCPLive spoke with Nyenhuis at AAAAI 2025 about ways to help patients with allergies despite the growing pollen seasons.

HCPLive spoke with Warren at AAAAI 2025 about a pilot study showing allergen-free food subscriptions reduced healthcare use but lacked significance.

Stallergenes Greer announced that Palforzia is now available for children under 4 years old with a peanut allergy, which follows the extended indication approval in July 2024.

A study at AAAAI 2025 found that dupilumab led to a 73.5% reduction in IgE levels at 24 months.